Exercise-associated hyponatremia is hyponatremia occurring during or up to 24 hours after prolonged exertion. In its more severe form, it manifests as cerebral and pulmonary edema. There have now been multiple reports of its occurring in a wilderness setting. It can now be considered the most important medical problem of endurance exercise. The Second International Exercise-Associated Hyponatremia Consensus Conference gives an up-to-date account of the nature and management of this disease. This article reviews key information from this conference and its statement. There is clear evidence that the primary cause of exercise-associated hyponatremia is fluid consumption in excess of that required to replace insensible losses. This is usually further complicated by the presence of inappropriate arginine vasopressin secretion, which decreases the ability to renally excrete the excess fluid consumed. Women, those of low body weight, and those taking nonsteroidal anti-inflammatory drugs are particularly at risk. When able to be biochemically diagnosed, severe exercise-associated hyponatremia is treated with hypertonic saline. In a wilderness setting, the key preventative intervention is moderate fluid consumption based on perceived need (''ad libitum'') and not on a rigid rule.
Introduction
Having first been reported a little more than 2 decades ago, 1,2 exercise-associated hyponatremia (EAH) has now come to be recognized as arguably the most important, serious medical problem in endurance sports participants. 3 Much research has followed these initial reports. For some time there was debate about its etiology between 2 firmly entrenched camps, supporting either the water intoxication 1 or the salt loss hypotheses. 4 More recently there has been an increasing consensus about the definition, manifestations, etiology, treatment, and prevention strategies for EAH.
EAH Consensus Statement
The consensus on EAH is represented in its most up-todate form by the Consensus Statement of the Second International Exercise-Associated Hyponatremia Consensus Development Conference, published last year in the Clinical Journal of Sports Medicine, 3 to which readers are directed for a more comprehensive review of EAH in general. The meeting, held in New Zealand in late 2007, brought together 18 researchers and experts in EAH from multiple disciplines and multiple countries to review all the existing data on EAH and update its 2005 statement. 5 Their stated aim with regard to EAH was to develop a document that could help to ''curtail the morbidity and mortality associated with the disorder.'' Notably the meeting was free of commercial sponsorship and used a recognized consensus conference protocol.
EAH is formally defined as hyponatremia (less than the laboratory reference range) occurring during or up to 24 hours after prolonged exertion (generally considered to be Ͼ4 hours' duration). The EAH consensus statement gives us a clear and updated view as to the manifestations, pathophysiology, risk factors, treatment, and prevention of EAH. It also highlights those areas that remain controversial and research questions that remain to be answered. Much of this knowledge can be applied to the wilderness setting.
Relevance to the wilderness setting
The direct relevance of a statement on EAH to our preferred wilderness environment may not seem obvious. The largest studies to date on EAH have been conducted in the setting of mass participation sporting events, such as endurance triathlons 6, 7 and conventional marathons. 8, 9 However EAH has been reported in hikers, 10 trekkers, 11, 12 climbers, 13 and cold climate endurance athletes. 14 It is likely that these reports understate the incidence of EAH given the difficulties of conducting large prospective studies in wilderness settings.
Manifestations
The most serious manifestations of EAH are primarily neurologic. Generally, symptoms are not obvious until the [Na ϩ ] falls below 130 mmol/L or there has been at least a 7% fall from the patient's baseline [Na ϩ ], 15 although large interindividual variation exists. 16, 17 However, the absolute serum [Na ϩ ] is less important than the patient's clinical status. The most serious symptoms and signs of EAH are reflective of pulmonary and cerebral manifestations of fluid overload and include noncardiogenic pulmonary edema 18 and cerebral edema with encephalopathy. Early symptoms include nausea, vomiting, and headache, and later signs include confusion, disorientation, seizures, coma, and the crepitations of pulmonary edema. In the wilderness setting, plausible differentials can include heat stroke, hypothermia, hypernatremia, and high-altitude cerebral edema.
Etiology and pathophysiology
In the majority of published cases, the primary etiologic factor in EAH is fluid consumption in excess of fluid losses. 3 In the resting state, maximal urine excretory rates are typically 800 to 1000 mL/hr, so prolonged fluid consumption above this rate can lead to dilutional hyponatremia. 19, 20 During exercise, however, sweating becomes the primary mode of water and sodium loss. Thus, athletes exercising at low intensities will require less fluid than when exercising at higher exercise intensities due to the decreased rate of metabolic heat production, leading to a smaller rise in body core temperature and a commensurate lower heat dissipation requirement. The exercising situation is further complicated by the stimulation of nonosmotic arginine vasopressin (AVP) secretion, which is the body's main antidiuretic hormone, during prolonged endurance events. 21, 22 AVP is now recognized as an exacerbating factor in most cases of EAH as a variant of the syndrome of inappropriate AVP secretion (otherwise known as syndrome of inappropriate antidiuretic hormone secretion [SIADH]). 23 AVP has a very short half-life, so research in this area has proved difficult. Nevertheless, what would be regarded as a normal AVP level at rest is physiologically inappropriate in the presence of hyponatremia or hypervolaemia. 24, 25 Many of the recognized stimuli to AVP secretion, such as exertion, nausea, vomiting, exertional hypovolemia, pain, and thermal stress, can occur in the wilderness. So the complex interplay between excessive fluid consumption and elevated AVP levels may lead to EAH with high or even more moderate levels of fluid intake and may in part explain the individual variability in the predisposition to EAH. In contrast to the strong evidence for excessive fluid consumption and elevated AVP levels in the development of EAH, no strong evidence currently exists for loss of sodium as the primary cause. However, one case of recurrent EAH in a lawn bowler carrying the cystic fibrosis gene mutation Delta F508 has recently been reported 26 with a sweat sodium value of 103 mmol/L, which represents the exception rather than the rule.
Risk factors
The profile of a ''typical'' athlete developing EAH is a slow, low-body weight, female taking nonsteroidal antiinflammatory drugs (NSAIDs). However, experienced and well-trained male athletes are not immune to developing this fluid balance disorder if sustained fluid intake exceed the capacity for fluid output. 27 The combination of exuberant fluid intake beyond thirst in combination with antidiuresis (from nonosmotic AVP secretion 21 with or without the potentiating effects of antidiuresis from the ingestion of NSAIDs 28, 29 ) can create conditions ideal for the development of EAH in both novice and experienced athletes in and out of the wilderness setting. It is noteworthy that both selective and nonselective cyclooxygenase inhibition by NSAIDs can inhibit free water clearance during exercise, suggesting that cyclooxygenase-2 inhibition at the kidney is important in the maintenance of renal function during physical activity. 30 Therefore, it is strongly advised that athletes refrain from ingesting NSAID medications while participating in sustained physical activity in the wilderness setting. Further identified risk factors of particular relevance to the wilderness setting include prolonged exercise duration and extremes of temperature. 10 These associations have been documented in research scenarios, but their presence does not necessarily imply causality and so they should only be used to identify at-risk groups.
Treatment
Treatment protocols for EAH are based on an urgent serum [Na ϩ ] estimation. Although this is technically feasible in a wilderness setting, 10 it is only likely to be available to fixed medical facilities, at large sporting events, or in particularly well-equipped mobile parties. Urgent treatment is required when EAH is biochemically confirmed and there are signs or symptoms of hyponatremic encephalopathy. In this situation, the aim is to rapidly administer an intravenous sodium load (but not a fluid load) to decrease cerebral edema and partially reverse the hyponatremia. The consensus statement recommends a 100-mL bolus of 3% NaCl repeated up to 2 more times at 10-minute intervals if there is no clinical improvement. 3 Wilderness care providers may prefer to use 20% NaCl as 15-mL boluses, because this is available in more portable ampoules and still has the same sodium content. In the hospital setting, an intravenous dose of 29.2% saline has been used with success in patients with critically low serum sodium concentrations with encephalopathy, 31 which suggests that this practice would be safe and most practical for medical personnel caring for athletes in a wilderness environment. This aggressive hypertonic saline treatment in EAH does not have the risk of osmotic demyelination known to occur when this therapy is used in chronic hyponatremia. The administration of an intravenous bolus of hypertonic saline is emergent if seizures associated with acute hyponatremic encephalopathy are present, because this regimen is the quickest and most efficient method currently available to reduce life-threatening cerebral edema. In the absence of a serum [Na ϩ ] measurement, hypertonic saline cannot be recommended. Importantly, EAH may be worsened by the use of 0.9% NaCl (normal saline) due to AVP mediated retention of the water component only. 32 Should EAH be suspected on clinical grounds but serum [Na ϩ ] testing not available, intravenous fluids can only be justified to treat frank hypovolemia. Withholding intravenous fluids may be counter to the ingrained, standard emergency response to the sick patient but may be potentially life saving. Similarly, limiting oral fluid intake until a healthy urine output is established will aid resolution of EAH. In all but the most serious cases, this may be all that is required. Should symptomatic EAH be suspected or confirmed, then evacuation to a definitive care facility is a priority, as would occur for any other medical emergency.
Prevention
As often as it is requested and as tempting as it may be, there is no one fluid intake regime that can be recommended for all sports and all situations. Any fluid intake regime during prolonged exercise that exceeds the typical sweat and urine excretory capacity (generally between 800 and 1000 mL/hr) must certainly be considered high risk. A more moderate fluid intake strategy is the desired norm, and the best advice is to drink ''ad libitum,'' that is, to perceived need and not to a predetermined rule. 33 Although drinking according to the dictates of thirst has repeatedly been shown to be effective at maintaining fluid homeostasis at rest in most mammalian species, suppression of the thirst mechanism during episodes of extreme physical activity requires further scientific investigation. 33 Nonetheless, defects in the thirst mechanism are rare, even in cases of inappropriate antidiuretic hormone secretion, 34 and should protect against the development of both life-threatening dysnatremia's of exercise: hyponatremia and hypernatremia. The aim should be never to gain weight during endurance exercise and expect a small percentage weight loss (1%-2%) when competing in endurance races secondary to substrate utilisation and the effects of glycogen loading. 33, 35, 36 Of note, in a controlled laboratory setting, a 2% decrement in weight loss has been shown to affect performance and cardiovascular variables. 37 However, the relevance of a mild degree (1%-2%) of body weight loss and potential deficits on performance in the wilderness setting may be of less practical importance in extreme conditions or during extreme events. It may be possible for individuals to better predict their own fluid requirements by weighing pre-and postexercise while participating in activity that replicates that expected for their upcoming endurance exercise. However, this practice and the strict usage of scales as a hydration guide has severe limitations in the wilderness setting, whereas nonosmotic stimulation of AVP may likely alter the reproducibility of such regimens. Other than appropriate fluid intake advice, there is no strong evidence that other strategies, such as sodium supplementation and the use of sports drinks, can limit the development of EAH. Trip leaders and wilderness care providers have an obligation to provide informed fluid intake advice and would be well advised to target known at-risk groups and appropriately limit fluid availability. The challenge of providing such advice and direction when pitted against commercial interests and lay misinformation should not be underestimated. 38 
Future research directions and conclusions
The consensus statement leaves us with some unanswered research questions about EAH. Many are suited to exploration by properly designed studies in a wilderness environment. Examples identified include those around the use of oral hypertonic saline solutions in treatment of EAH and the use of sodium supplementation to prevent EAH. Even in the absence of prospective studies, clinicians are encouraged to submit case reports to the International EAH Registry, which can be found at www.overhydration.info. This site also contains substantial amounts of educational material useful in spreading the message that EAH is a significant medical risk in endurance exercise and that the key preventive strategy is to encourage moderate fluid intake ''ad libitum.''
